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MACROPHAGE MIGRATION INHIBITORY FACTOR POLYMORPHISMS AND 
INVASIVE STREPTOCCUS PNEUMONIAE INFECTIONS 
Sarah B. Doernberg, Richard Bucala, Vincent J. Quagliarello.  
Department of Medicine, Yale University School of Medicine, New Haven, CT. 
Streptococcus pneumoniae (S. pneumoniae) causes a spectrum of disease severity, and human host 
factors likely play a role in this variation. One candidate factor is macrophage migration inhibitory factor 
(MIF), a pro-inflammatory cytokine and upstream regulator of innate immunity. The MIF promoter 
contains two functional polymorphisms, a tetranucleotide (CATT) repeat such that MIF expression 
increases with repeat number from 5-8 and a single nucleotide polymorphism (SNP) leading to a G-to-C 
transition, which results in increased MIF expression in cell line reporter assays. Emerging data suggest an 
association between high-expression MIF alleles and inflammatory disease. This study comprised two 
parts. For the in vitro portion, we hypothesized that peripheral blood monocytic cells (pBMCs) 
cultured from healthy individuals with low-expressing MIF genotypes (5-CATT alleles or SNP-
GG) would have lower MIF content and release than those from individuals with high-expressing 
MIF genotypes (7-CATT or SNP-C alleles). For the in vivo study, we hypothesized that individuals 
with low-expressing MIF genotypes would have less severe systemic inflammatory responses than 
individuals with high-expressing MIF genotypes in response to S. pneumoniae infection. Blood samples 
and chart findings were collected prospectively at three Connecticut hospitals from 30 inpatients with 
documented invasive S. pneumoniae infections. Genomic DNA was isolated from host blood, amplified, 
and genotyped using fragment analysis (CATT repeat) and allelic discrimination (SNP) methods. Fisher’s 
exact tests were used to compare genotypes and disease severity. For the in vitro experiments, there were 
no differences observed in serum MIF levels or MIF content or release from pBMCs based on MIF 
genotype. In the cohort of patients infected with S. pneumoniae, serum MIF levels among enrolled subjects 
were significantly higher than the reported normal values, but levels did not vary with genotype or disease 
severity. The SNP genotype was not correlated with disease severity or occurrence of meningitis. The 
CATT genotype did not correlate significantly with disease severity or occurrence of meningitis, although 
there was a trend suggesting an association between the 7-CATT allele and meningitis (p = 0.1188, 8% 
without meningitis had a 7-CATT allele vs. 40% with meningitis). More patient samples will need to be 
analyzed in order to definitively elucidate the role of MIF genetics in infection with S. pneumoniae.
 iii
ACKNOWLEDGEMENTS 
 I would like to thank my advisors, Richard Bucala and Vincent Quagliarello for their 
support, guidance, and mentorship throughout this process. I would also like to thank all members 
of the Bucala lab for their camaraderie, expert advice, and extra hands. In particular, Anna Beitin 
and Lin Leng helped with the genotyping assays. Courtney McDonald always knew where to find 
things in lab and was willing to lend a hand at any time. Regardless of how busy they were with 
their own work, Jason Griffith and Jeremy Moss were available to help me with experimental 
design, lab work, data analysis, and writing. Without the help of the staff at the Microbiology 
laboratories at Hospital of Saint Raphael, Saint Francis Hospital, and Yale-New Haven Hospital, 
the identification of patients would not have been possible. Harry Conte at Saint Francis Hospital 
and Holenrasipur Vikram at the Hospital of Saint Raphael served as internal physician contacts 
and were helpful with tracking down attendings, patients, and medical records. Marilyn Powers in 
the Infectious Diseases office was always friendly and accommodating. I am grateful to the 
wonderful comments, help, and support from Mark Siegel, my faculty reviewer. The Yale Office 
of Student Research supported this work financially. The Yale University School of Medicine has 
been an incredibly supportive place to learn all aspects of medicine. I would like to thank my 
friends for their kindness and encouragement. Lastly, I am continually grateful to my parents and 
sister for their love and support.  
 iv
TABLE OF CONTENTS 
 
Introduction...................................................................................................................................... 1 
Specific aims and hypothesis ......................................................................................................... 21 
Materials and Methods................................................................................................................... 22 
Results............................................................................................................................................ 29 
Discussion...................................................................................................................................... 48 
Bibliography .................................................................................................................................. 55 
 
 v
TABLE OF FIGURES 
Figure I- 1. MIF promoter and gene .............................................................................................. 16 
Figure I- 2. Gram-positive cell wall............................................... Error! Bookmark not defined. 
Figure 1. THP1 cells treated with varying concentrations of LPS................................................. 30 
Figure 2. MIF release from THP-1 cells treated with LPS ............................................................ 31 
Figure 3. Cell integrity of THP-1 cells treated with LPS............................................................... 31 
Figure 4. MIF content and release from THP-1 cells treated with LPS or PGN ........................... 32 
Figure 5. Cell integrity of THP-1 cells. Cell death measured by LDH release.............................. 32 
Figure 6. Basal afternoon serum MIF levels from individuals with known CATT genotypes...... 33 
Figure 7. Basal MIF stored in pBMCs from individuals with different CATT genotypes ............ 34 
Figure 8. Basal MIF released from pBMCs from individuals with different CATT genotypes .... 35 
Figure 9. MIF released from pBMCs of individuals with different genotypes stimulated with LPS
............................................................................................................................................... 36 
Figure 10. Patient enrollment......................................................................................................... 37 
Figure 11. Race/ethnicity of enrolled subjects............................................................................... 39 
Figure 12. MIF levels and severity of infection............................................................................. 41 
Figure 13. MIF levels and type of infection................................................................................... 42 
Figure 14. Serum MIF levels and SNP–173 genotype................................................................... 42 
Figure 15. Serum MIF levels and 5-CATT genotype .................................................................... 43 
Figure 16. Serum MIF levels and 7-CATT genotype. ................................................................... 43 
Figure 17. Distribution of a series of 168 control genotypes......................................................... 46 
 
 vi
TABLE OF TABLES 
Table 1. Baseline Characteristics. .................................................................................................. 38 
Table 2. Source of infection........................................................................................................... 39 
Table 3. Presenting signs and symptoms. ...................................................................................... 39 
Table 4. SNP –173 genotype and disease severity......................................................................... 44 
Table 5. SNP-173 Genotype and CNS infection............................................................................ 44 
Table 6. MIF CATT genotypes and severity of infection.............................................................. 45 
Table 7. Lack of association between 5-CATT alleles and disease severity.. ............................... 46 
Table 8. Lack of association between 7-CATT allele and disease severity................................... 46 
Table 9. MIF CATT genotypes and type of infection.................................................................... 47 
Table 10. Lack of association between 5-CATT alleles and disease type. .................................... 47 
Table 11. Trend towards association between 7-CATT allele and disease type............................ 47 
 1
“It is our response to their presence that makes the disease” 
Lewis Thomas, 1972 (1) 
INTRODUCTION 
The human immune system has evolved to protect against tissue invasion by infectious 
pathogens or host cellular antigens (e.g., tumor antigens). Although the host response is usually 
effective, disease can ensue if the response is unsuccessful or too robust. For example, an 
overactive immune response directed against self-antigens results in autoimmune disease; a 
strong response against invasive bacteria can result in complications such as septic shock (2). 
Over the past century, scientists have discovered how the immune system recognizes foreign 
antigens, recruits and influences immune cells, and destroys the invading agent (3). Recent efforts 
have focused on secreted proteins of the innate immune system, the host’s first defense against 
foreign molecules, which result in cascades leading to an inflammatory response. Therapies 
directed against specific mediators in these cascades may be effective in preventing much of the 
damage of inflammatory and infectious diseases without the many systemic side effects that 
occur with broad-spectrum immunosuppressants such as steroids. Presently, these specific 
therapies only exist for chronic inflammatory diseases, such as rheumatoid arthritis, and have not 
yet been proven effective for infectious diseases (4, 5). 
Immune response to severe infection: Sepsis  
Systemic infection, or sepsis, is a major and growing problem that illustrates the central 
role for innate immunity in disease pathogenesis (6). It occurs in response to many types of 
infections and is characterized by systemic response to infection. This systemic response results 
in widespread inflammation with vasodilation, microvascular leakiness, and leukocyte invasion 
into organs distant from the initial insult. Clinical sepsis occurs as a spectrum of severity, which 
has now been defined for investigative and therapeutic purposes (7, 8). Sepsis is described first as 
infection along with clinical signs indicating the systemic inflammatory response syndrome 
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(SIRS), which requires the presence of abnormalities in at least two of the following categories: 
temperature, heart rate, respiratory rate, and white blood cell count. Severe sepsis involves the 
additional presence of end-organ damage as manifested by characteristics such as hypoxia, lactic 
acidosis, oliguria, disseminated intravascular coagulation, or altered mental status. Septic shock 
occurs when sepsis is associated with a hypotension that persists despite adequate fluid 
resuscitation.  
Despite advances in antimicrobial therapy, sepsis continues to cause significant morbidity 
and mortality. One study based on a review of non-federal, acute hospitalizations across the 
United States over a 22-year period found the rate of sepsis increased almost 9% per year to 
660,000 cases in 2000, which resulted in an incidence of 240.4 cases per 100,000 population (9). 
The authors of this study attributed this rise to higher rates of microbial resistance, more HIV-
positive patients, growth in organ transplantation and chemotherapy programs, and greater use of 
invasive devices and procedures. Throughout this period, both males and non-whites showed 
higher rates of sepsis than females and white populations. Mortality rates declined among those 
with gram-negative sepsis but remained unchanged among those with gram-positive infections, 
which experienced increasing incidence throughout the study period. In addition, the study found 
that the mortality rate increased from 15% in those without any organ dysfunction to 70% in 
those with three or more failing organs. Several other epidemiological studies have also shown 
increasing incidences and high mortality rates over recent years (10, 11). Because its categories 
have been so well defined, sepsis is a useful way to study the progression of infectious diseases. 
When a host is faced with an infectious insult, the immune response can be characterized 
as inadequate, sufficient, or excessive (12). A deficient response will result in overwhelming 
infection while an adequate one can result in eradication of the insult. This immune response to 
infection involves a coordinated series of events that may also end in an overactive, uncontrolled 
“cytokine storm,” often leading to vascular collapse, organ system failure, and possibly death. 
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From the time the microbe invades into the tissue, there are a number of points in both the innate 
and adaptive immune responses during which slight variation could contribute to a deleterious 
outcome (13, 14). The initial threat signal to the host involves membrane-bound extracellular 
receptors on mononuclear phagocytes, such as monocytes, macrophages, and dendritic cells, 
which recognize foreign molecules. These so-called pattern recognition receptors (PRRs) include 
the Toll-like receptor family, which recognize microbial products, or pathogen-associated 
microbial patterns (PAMPs), such as lipopolysaccharide, peptidoglycan, superantigens, viral 
nucleic acids, and endogenous heat-shock proteins (15). As outlined by Medzhitov and Janeway, 
binding of a PAMP to a PRR results in signal amplification and eventual mounting of an anti-
microbial response. The specifics of this response are complex. For instance, this cascade often 
involves release of nuclear factor (NF)-κB from its inhibitor I-κB and translocation to the 
nucleus. Once in the nucleus, NF-κB influences transcription of numerous pro- and anti-
inflammatory cytokines. In turn, these cytokines act through receptors and co-factors on specific 
cells to initiate their own signal transduction cascades resulting in specific products and actions of 
immune and endothelial cells. Many of these cytokines have multiple actions, resulting in 
production of vasoactive substances, oxygen free radicals, and other inflammatory molecules, 
leading to an intricate but controlled web of mediators and recruitment of other cell types to the 
area of injury or infection. The complement system is also activated and contributes to the 
outpouring of inflammatory mediators. In addition, there is systemic release of hormones such as 
catecholamines and corticosteroids, which modulates the overall systemic response to tissue 
invasion.  
The coagulation and fibrinolytic cascades are closely tied into this inflammatory 
response, and sepsis results in a pro-coagulant state (16). As reviewed by Matthay, release of 
tissue factor as a result of direct cellular injury and the action of pro-inflammatory cytokines on 
monocytes and endothelial cells leads to a series of events resulting in thrombin production and 
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fibrin deposition, which in turn up-regulates much of the pro-inflammatory response. Increased 
levels of plasminogen-activator inhibitor type-1 (PAI-1) promote coagulation by preventing 
plasmin generation and degradation of fibrin clots. In turn, there is a relative deficiency of the 
anticoagulant molecules activated protein C (APC), antithrombin, and tissue factor pathway 
inhibitor. As a result, small vessels often clot off, resulting in decreased organ perfusion. 
Consequently, the pro-inflammatory response of sepsis often disrupts the homeostasis of the 
coagulation cascade, which further contributes to the organ damage. 
There is an anti-inflammatory component that occurs simultaneously with the activation 
of the pro-inflammatory response (17). This counter-response includes anti-inflammatory 
molecules, such as the soluble TNF-α receptor and the IL-1 receptor antagonist, which act to 
downregulate cytokine activity, as well as anti-complement molecules and pro-inflammatory 
molecules such as IL-10. Lymphocyte apoptosis is upregulated in septic patients as compared 
with non-infected critically ill individuals (18). Whether this anti-inflammatory response 
sufficiently counterbalances the pro-inflammatory response or results in overcompensation and a 
worsening of morbidity and mortality may vary in different patients and be a feature of the 
dysregulated response in severe sepsis.  
Ultimately if the response goes unchecked, the inflammatory and pro-coagulant cascades 
together contribute to vascular instability, tissue hypoxia, microvascular occlusion, and 
myocardial depression; organ compromise and irreversible tissue damage ensue (19). Despite the 
advances in understanding of the sepsis syndrome, there has been relatively little data to support 
specific treatments aimed at the underlying pathophysiology, though there is active research 
looking for clinical sub-populations that may benefit from targeted therapy (20). Recombinant 
activated protein C (APC; Drotrecogin Alpha), an anti-inflammatory and thrombin inhibitor 
molecule, is one such therapy that may benefit those with severe sepsis at very high risk of death 
(21). The lack of success with APC in patients with lower risk of death emphasizes the need for 
 5
accurate identification of candidate groups prior to these targeted treatments (22). It is still 
unclear how to identify accurately the appropriate patient group for such therapy, and genetic 
variation may play a role in defining candidate subgroups.  
Immune response to severe infection: Meningitis 
Bacterial meningitis is another serious infection in which the immune response plays a 
seminal role in disease pathophysiology. There are several ways in which meningeal infection can 
occur. Commonly, bacteria adhere to and colonize the nasopharyngeal mucosa, invade the 
intravascular space, enter through the blood-cerebrospinal fluid (CSF) barrier, and then survive 
within the subarachnoid space (23). Alternatively, infection can occur by direct spread from the 
sinuses or otitis media. Seeding of the CNS from bacteremia due to distant infections can also 
happen. In the age of antibiotics, community-acquired meningitis has a case-fatality rate of 
approximately 25% (24, 25). As with the sepsis syndrome, many of the complications of 
meningitis involve dysregulation of the host inflammatory response, which can lead to 
neurological as well as systemic sequelae (26). Bacterial products in the blood and the CSF 
engage endothelial PRRs, which leads to cytokine release, resulting in recruitment of 
inflammatory cells, increase in endothelial permeability, and upregulation of leukocyte adhesion 
molecules. This response interrupts the blood-brain barrier and results in cerebral edema, 
impaired cerebral blood flow, and vasculitis. Toxic free radicals released by both bacteria and 
inflammatory cells contribute to neuronal cell death. As a result, focal and global neurological 
deficits ensue. Patients with meningitis can die either from neurological complications, such as 
ischemia, hemorrhage, or edema, or from complications from the systemic response to a severe 
infection (27). As with sepsis, mortality remains high despite appropriate antibiotic use.  
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Evidence for genetic basis of infection 
Variation between individuals with infectious insults provides a way to examine the role 
of the host response in disease severity and outcome. In disorders like sepsis and meningitis 
where the immune cascade plays a major role, it is no surprise that genetics are an important 
determination of disease course. While environmental exposure and microbial virulence factors 
undoubtedly play an important part, there is a genetic component that dictates whether an 
organism is able to cause clinically significant disease or not. For example, a longitudinal study 
of premature death in adoptees born between 1924 and 1926 and their biological and adoptive 
parents by the Danish Adoption Register demonstrated a strong genetic component to infection 
(28). The authors found a 5.81 (95% CI, 2.47 to 13.7) relative risk of death in an adopted child 
whose biological parent died before the age of 50 of an infection compared with an adoptee 
whose biological parents lived past 50 years of age. Death of an adoptive parent from infection 
before age 50 did not increase the risk of death in the adoptee compared with those whose 
adoptive parents survived past 50 years of age. Surprisingly, the converse was true with cancer 
where premature death of an adoptive, but not a biological, parent from cancer led to a 5.16 
relative risk of death (95% CI, 1.20 to 22.2) in the child. Twin studies comparing dizygotic to 
monozygotic twins, groups that presumably have similar environmental exposures but different 
levels of genetic overlap, generally have shown a greater concordance to susceptibility or 
response to infection among monozygotes (29, 30, 31, 32). Although the evidence for a role of 
genetics in infectious diseases is strong, finding which specific genes play a determinant role will 
prove a great challenge. Variation in the host response to invading organisms likely accounts for 
the hereditary patterns since infection itself is not a genetic disease (33). 
The classic way to identify hereditary single gene defects is through linkage analysis, 
which utilizes known chromosomal loci that are inherited in the same pattern as the gene of 
interest. However, in the case of infectious diseases, traditional Mendelian inheritance of a single 
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gene leading to susceptibility is rare. An example of this is immunodeficiency caused by the x-
linked absence of Bruton’s tyrosine kinase leading to agammaglobulinemia and susceptibility to 
infection by different extracellular organisms (34). Hereditary predispositions to specific 
infections, such as an autosomal recessive mutation of the interferon-γ receptor resulting in 
mycobacterial infections, have also been reported (35). Yet, despite the compelling evidence for 
genetic susceptibility to infectious diseases, such classic inheritance patterns are the exception. 
One theory to explain this disparity is the polygenic hypothesis, which posits that several 
common mutations, each of which has minor consequence alone, combine to result in increased 
susceptibility within a certain individual (36). It is likely that a mixture of subtle variations in the 
immune cascade can lead to certain susceptibilities in many individuals. In the cases where 
genetic mutations exert a large effect on the susceptibility to infection, classic linkage analysis is 
helpful, but when these alterations exert a smaller contributing effect, other strategies need to be 
implemented in order to identify involved genes.  
There are several related approaches to the elucidation of the complex genetics 
underlying the immune response to infection (37). Now that the human genome has been cloned, 
scientists have found many polymorphisms, alleles that co-exist in a population in a stable 
proportion at a frequency higher than would be accounted for by random mutation. The 
substitution of one base pair for another, known as a single nucleotide polymorphism (SNP), is 
the most common form of these polymorphisms, occurring every 300-600 base pairs (38). These 
SNPs arise both within a codon, causing an amino acid substitution that can alter protein 
structure, and in the 3’ or 5’ non-coding regions, where the modification can affect transcription 
factor binding affinity or efficiency. One common tactic in the study of the genetic basis for 
infection is use of associative studies that compare frequencies of polymorphisms in likely 
candidate genes between ethnically matched groups or in affected and non-affected family 
members. However, these studies must be carefully designed and analyzed because they are 
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difficult to reproduce, confounded by ethnic variation, subject to publication bias, and at risk for 
both type I and type II error (39). In addition, polymorphisms are often inherited preferentially 
alongside other neighboring polymorphisms, in a pattern known as linkage disequilibrium (40). 
Thus, once a polymorphism is shown to be associated with a particular disease, the specific 
combination polymorphism with neighboring polymorphisms, called a haplotype, needs to be 
examined to determine which polymorphism in that region specifically contributes to the 
phenotype under study.  
A similar method utilizes the concept of linkage disequilibrium without relying on 
guessing a candidate gene that may be involved in disease. This strategy involves genome-wide 
scans that attempt to find SNPs that segregate with disease in a population or family (41). A 
related approach uses haplotypes, or collections of SNPs, in association studies without any 
assumptions of which specific SNP is the crucial contributor to disease variability. Because each 
polymorphism likely acts in concert with many others as well as with environmental and 
microbial factors, the mapping of complex diseases is not straightforward. Microarray technology 
is now allowing for analysis of multiple candidate genes based on differential levels of expression 
(42). Even in an ideal setting, these observational studies of candidate polymorphisms only 
demonstrate association and should be used as a starting point for further studies. Genetic studies 
knocking out genes in animals such as mice and fruit flies also have contributed to the 
identification of candidate genes for human studies (43). 
The TNF-α molecule, which is encoded on the highly variable human leukocyte antigen 
(HLA) region on chromosome 6, is likely the best-studied part of the immune cascade with 
regards to the genetics of infections. The promoter of this cytokine contains an SNP at position –
308, in which 30% of the Caucasian population has an A instead of a G (44). The less common 
version of the gene (A), referred to as TNF2, shows a significantly higher level of both 
spontaneous and induced transcriptional activity compared with the TNF1 version. This allele is 
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linked to the HLA-DR3 haplotype, which has in turn been associated with higher TNF-α levels in 
vivo and in vitro (45, 46). This cytokine plays an integral role in immune defense but in certain 
cases can be harmful when expressed in excess. It is increased in individuals with septic shock, 
and it can reproduce the shock syndrome in animal studies. The TNF-α polymorphism has been 
studied with respect to a number of infectious diseases. The high-expressing TNF2 allele was 
associated with a 7-fold increase in death or neurological disability in cerebral malaria, a 2.5-fold 
increase of death in meningococcal disease, and an amplified susceptibility to and 3.7-fold 
increase in death from septic shock (47, 48, 49, 50). Illustrating the challenges of association 
studies, these findings have not been corroborated by all investigators (51, 52). This discrepancy 
may be due to linkages with another HLA locus or could be due to a combination of other factors 
such as the spectrum of ethnicities studied. 
Several other candidate genes also contain functional polymorphisms that have been 
hypothesized to play a role in sepsis, including TNF-β, interleukin-1 receptor antagonist, 
interleukin 6, the LPS receptor CD-14, and TLR4 (53, 54, 55, 56, 57, 58, 59, 60). Other 
candidate genes, such as tissue-plasminogen activator (t-PA), heat shock protein, and LPS-
binding protein, have been studied and shown to have no association with infections (61, 62). 
Though the findings in these studies have not yet translated into improved outcomes, one can 
imagine a future where physicians have the capacity to identify individual polymorphisms and 
provide a gene-targeted therapy. For instance, preliminary studies of anti-TNF-α antibodies in 
individuals with sepsis have not proven effective (63, 64). In light of the studies that have shown 
the association of TNF-α promoter polymorphisms with septic shock, it may be that the 
antibodies could be helpful in a subset of infected individuals with the high-expressing 
polymorphism and severe disease. 
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Macrophage migration inhibitory factor as a candidate gene involved in severe infections 
Macrophage migration inhibitory factor (MIF) is an upstream inflammatory mediator 
implicated in disease pathogenesis that remains a candidate for genetic studies similar to those 
with TNF-α. One of the first cytokine activities described in the 1960s, MIF initially was 
described as a soluble lymphocyte supernatant protein from tuberculin-hypersensitive guinea pigs 
that inhibited the migration of normal peritoneal macrophages in vitro (65, 66). Over the next 
decades of research, this lymphocyte substance was found to augment many macrophage 
functions, including adherence, spreading, motility, phagocytosis, and metabolism (67, 68). The 
initial studies did not identify MIF expressly as a source of these pro-inflammatory actions and, in 
fact, relied on T-cell supernatants, which contained a mixture of MIF and other mediators, 
including interleukin-4 and interferon-γ, substances that also exhibit migration inhibitory activity 
on monocytes. The specific role of MIF in triggering this macrophage activation was confirmed 
once the protein was molecularly cloned (69, 70, 71). Though these studies established MIF as a 
cytokine, this protein had more functions and more cellular sources than originally considered. 
In addition to its role in the immune response, MIF was being studied simultaneously for 
its position in the endocrine system. The murine homologue of MIF was discovered as a major 
protein secreted by the anterior pituitary cell line AtT-20 and by whole pituitary glands in 
response to systemic lipopolysaccharide (LPS, gram negative endotoxin) injection (72). Pools of 
pre-formed MIF protein and increased pituitary MIF mRNA levels were measured in these 
cultured pituitary glands in response to LPS. To examine the role of systemic MIF in an in vivo 
murine model of septic shock, this same group also showed that co-injection of recombinant MIF 
with intraperitoneal LPS yielded a higher death rate. Anti-MIF antibodies protected from this 
lethal endotoxemia. Between its macrophage-activating and endocrine functions, it became clear 
that MIF had far-reaching and important effects on the early immune response to bacterial 
stimuli. 
 11
Though these early studies supported MIF as a product of pituitary and T cells, there was 
an unexpected initial MIF peak in the serum of T cell-deficient, hypophysectomized mice injected 
with LPS (73). Further experiments to elucidate the source of this initial release demonstrated 
that both human and mouse macrophage/monocyte cell lines contained significant pools of pre-
formed MIF. The RAW 264.7 macrophage cell line demonstrated an increase in mRNA levels in 
response to LPS. Interestingly, MIF secretion and mRNA induction decreased at high 
concentrations of LPS. The authors of this study suggested that macrophage-derived MIF may 
work together with TNF in an initial response to infection and that pituitary- and T-cell-derived 
MIF may be responsible for a systemic response to a continued, invasive threat. The MIF protein 
is pre-made, stored intracellularly, and relies on an atypical protein-secretion pathway that does 
not use an amino-terminal leader sequence (74). Subsequent studies have supported the concept 
that MIF can override glucocorticoid-mediated anti-inflammatory actions. MIF expression occurs 
in most cells of the immune system as well as many tissues throughout the body, including the 
brain, lung, liver, adrenal gland, and skin (75). The constitutive expression across many cell types 
allows for a rapid pro-inflammatory response. 
In a somewhat surprising discovery, low levels of glucocorticoids, molecules that 
generally result in immunosuppression and decreased inflammation, promoted MIF release (76). 
This release from murine macrophages occurred in a bell-shaped dose-response curve, and rats 
injected with dexamethasone also showed increased serum MIF levels. MIF treatment of human 
peripheral blood monocytic cells (pBMCs) overcame glucocorticoid-mediated 
immunosuppression of the macrophage cytokines TNF-α, IL-1, IL-6, and IL8, supporting the pro-
inflammatory function of MIF. At higher glucocorticoid levels, MIF lost the ability to 
counterbalance the steroid-induced immune suppression, which may indicate a natural defense 
against an overwhelming pro-inflammatory response. Further experiments with animal models 
demonstrated that recombinant MIF injection blocked dexamethasone protection from lethal LPS 
endotoxemia. As with many other homeostatic hormone systems such as insulin and glucagon or 
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PTH and calcitonin, MIF acts to counter-regulate the anti-inflammatory effects of 
glucocorticoids. 
Subsequent studies have supported the idea of MIF overcoming glucocorticoid anti-
inflammatory actions. In fact, many of this cytokine’s pro-inflammatory effects directly 
antagonize glucocorticoid actions. In human volunteers, MIF and cortisol showed a similar 
circadian pattern, and ingestion of cortisone led to increased levels of MIF (77). Hydrocortisone 
normally blunts LPS-induced increases in NF-κB, TNF-α-stimulated augmentation of arachidonic 
acid, and T-cell proliferation and cytokine production; MIF prevents these effects (78, 79, 80). In 
critically ill patients, MIF levels correlate closely with glucocorticoid levels, and the levels of 
MIF increase with increasing severity of sepsis or ARDS (81). MIF released from 
monocytes/macrophages and T-cells likely acts in a local manner to balance the anti-
inflammatory effects of glucocorticoid hormones.  
In addition to its ability to check the action of corticosteroids through stimulation of 
macrophage cytokine expression, MIF has many other pro-inflammatory roles in the innate and 
adaptive immune responses, including generation of matrix metalloproteinases, arachidonic acid 
products, and T-cell cytokines (82, 83, 84). MIF increases insulin release and glucose utilization 
and activates transcription factors for several pro-inflammatory mediators (85). It inhibits LPS-
induced p53-dependent apoptosis and directly increases responsiveness to endotoxemia by 
augmenting the expression of TLR4, the signal transducer for LPS (86, 87). MIF appears to be 
involved in an early part of the inflammatory cascade. It is likely that MIF acts as part of a 
network of cytokines that normally functions to control invasive stimuli; in certain situations this 
network can be dysregulated and contribute to, rather than protect against, disease. As a part of 
this network, MIF and TNF-α appear to function in a feedback loop with each cytokine in turn 
provoking increased release of the other.  
Bacterial invasion is likely one stimulus that this cytokine network acts to control. The 
role of MIF in animal models of infection has been looked at most closely with gram-negative 
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bacteria. Normally, MIF plays an essential role in control of infection, but as with TNF-α, excess 
expression can be maladaptive. As discussed above, LPS stimulates MIF release both in vivo and 
in vitro. In turn, recombinant MIF exacerbates while anti-MIF antibodies prevent LPS-induced 
lethality in mouse models (88). Mif knockout mice showed resistance to LPS-lethality, cleared 
intra-tracheal Pseudomonas aeruginosa, and had lower serum TNF-α levels compared with wild-
type mice (89). Wild-type mice showed high local and systemic levels of MIF release in response 
to intraperitoneal Escherichia coli injection or cecal ligation and puncture (CLP), a model of 
polymicrobial sepsis (90). In addition, TNF-α-deficient mice, which model immunodeficiency, 
showed a 62% survival rate when injected with anti-MIF antibodies following CLP compared 
with a 0% survival rate when injected with control antibodies. This result helped establish the 
intrinsic effects of MIF in the absence of TNF-α-mediated effects. The anti-MIF antibodies 
remained protective up until 8 hours after infection in wild-type mice undergoing CLP or E. coli 
injection as well. When co-injected into mice with E. coli, MIF led to a 40% increase in 
mortality. Not all studies support the above data correlating MIF to lethality from infection. For 
example, one group reported that neutralization of MIF with antibodies enhanced susceptibility to 
bacterial superinfection after CLP while treatment with recombinant MIF prevented infection 
(91). In addition, all MIF-deficient mice (Mif -/-) inoculated with Salmonella typhimurium, an 
intracellular bacterium, died within 25 days compared with only 50% of wild-type mice, and this 
increased mortality was associated with a decreased Th1 cytokine response (92). Clearly, the role 
of MIF in gram-negative infections is not easy to simplify, and likely there is variation in the 
response to specific bacteria. 
The position of MIF in the response to gram-positive bacterial infections has been studied 
as well, especially the host response to gram-positive exotoxins. Treatment of mouse macrophage 
cell lines (RAW 264.7), primary murine peritoneal macrophages, and mouse corticotrophic cell 
lines (AtT-20) with either Staphylococcus aureus toxic shock syndrome toxin-1 (TSST-1) or 
Streptococcus pyogenes exotoxin A (SPEA), both T-cell superantigens, led to a bell-shaped MIF 
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response (93). As with LPS and glucocorticoid stimulation of macrophages, MIF was released at 
lower concentrations of the exotoxins but not in response to higher concentrations. Similar to the 
bell-shaped dose-response curve to LPS, this prevention of release at high concentrations of toxin 
may be a natural protection against an overwhelming pro-inflammatory response to infection or 
trauma. On the other hand, the inhibition could also be an effect of the bacteria to paralyze the 
immune system. Injection of anti-MIF antibodies prior to a lethal dose of TSST-1 in BALB/c 
mice increased survival from 8 to 54%. Another series of experiments with Mif -/- mice 
demonstrated low levels of TNF-α release and resistance to a normally lethal injection of 
Staphylococcus aureus enterotoxin B (94). While some gram-positive organisms produce shock 
through exotoxins (e.g. staphylococcal and streptococcal toxic shock syndromes), others isolated 
during sepsis do not produce such superantigens and act via different means. Though more 
research needs to be completed in this area, one unpublished study found that mice with 
Streptococcus pneumoniae pneumonia, a non-toxin driven disease, treated with anti-MIF 
antibodies demonstrated increased survival associated with lower cytokine production 
(unpublished data, referenced in 95). 
In humans, median serum MIF levels are elevated in septic shock (17.8 ng/ml in 9 
patients) and severe sepsis (12.2 ng/ml in 7 patients) when compared with healthy individuals 
(2.2 ng/ml: 96, 97). Bronchoalveolar lavage samples from patients with acute respiratory distress 
syndrome (ARDS) show higher levels of MIF than normal volunteers. High MIF levels also have 
been associated with fatal outcomes in sepsis (98, 99). PBMCs from patients with sepsis showed 
increased spontaneous and induced (in response to LPS and heat-killed bacteria) release of MIF 
when compared with those from healthy controls (100). Interestingly, pBMCs from septic 
patients treated with glucocorticoids/mineralocorticoids released less MIF in response to LPS, 
peptidoglycan, and heat-killed E. coli compared with septic patients not given corticosteroids. 
This evidence varies from the in vitro experiments discussed above where steroid exposure led to 
a bell-shaped MIF response and may be increasingly relevant as the use of steroids in sepsis has 
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come back en vogue and has been shown to increase survival in certain subpopulations (101). 
Adrenal insufficiency most likely results in higher MIF levels because the corticosteroid-MIF 
dyad is thrown off, and this increased MIF level could contribute to morbidity from the 
inflammatory response to infection. The improved outcomes in patients with sepsis and adrenal 
insufficiency treated with corticosteroids could be due in part to the suppression of MIF release 
that is seen with the pBMC data.  
MIF levels have also been examined in non-infectious human diseases, and in general, as 
with infection, higher levels correlate with worse disease. High serum MIF levels have been 
found in diverse diseases such as rheumatoid arthritis, systemic lupus erythematosus, cancer, and 
pre-eclampsia when compared with control populations (102, 103, 104). Furthermore, these 
elevated serum MIF levels have been correlated with disease activity in several inflammatory 
diseases, including Crohn’s disease, multiple sclerosis, and Guillain-Barré syndrome (105, 106, 
107). These data, along with the basic science results placing MIF centrally in the pro-
inflammatory cascade, make MIF a good candidate for studies of disease pathogenesis and for 
therapy. MIF has the capacity to tautomerise several non-physiological substrates, and this 
catalytic site serves as a target for therapy with inhibitors (108). In addition, anti-MIF antibodies 
remain a potential source of therapy as well. 
Genetics of MIF 
With its central role in inflammation, individual variability in MIF expression may help 
contribute to susceptibility to or outcome of inflammatory diseases, akin to TNF-α. The MIF gene 
is found on chromosome 22q11.2 and, as discussed above, is expressed constitutively by many 
cell types. Recent work has identified CD74, a transmembrane protein, as a receptor for MIF, 
which is required for many, if not all, downstream activities such as activation of the extracellular 
signal-regulated kinase-1/2 (ERK-1/2)-mitogen-activated protein kinase (MAPK) cascade, 
cellular proliferation, and prostaglandin production (109). MIF has been reported to work via 
 16
intracellular pathways as well, and its diverse actions most likely occur through diverse pathways 
(110). 
The promoter region of the MIF gene contains two functional polymorphisms (see Figure 
I-1 below). The first polymorphism described is a series of five to eight CATT repeats (referred 
to henceforth by numbers from 5-8) occurring in the –794 position of the MIF promoter (111). As 
summarized by Baugh and colleagues, gene reporter assays showed decreased transcription of the 
alleles with 5 CATT repeats compared to the 6, 7, and 8 CATT repeat constructs. The initial case-
control association study with this polymorphism found that Caucasian rheumatoid arthritis 
patients with two 5-CATT alleles had lower MIF expression and less severe disease than those 
with at least one 6-, 7-, or 8-CATT allele. In addition, the proportion of individuals carrying at 
least one of the 5-CATT alleles decreased incrementally from the normal population to the mild 
arthritis group and the severe arthritis group. The promoter region contains a series of 
transcription factor binding sites, including the pituitary specific factor known as pit-1, although 





































Figure I- 1. MIF promoter and gene. The CATT-repeat polymorphism at position –794 and the G/C SNP 
at position –173 are illustrated in gray. Modified with permission from Richard Bucala. 
The second MIF promoter polymorphism described is a G-to-C transition occurring at 
position –173 in the MIF promoter that was associated with an increased risk of systemic-onset 
juvenile idiopathic arthritis (JIA) in an initial case-control study of Caucasian children from the 
UK (112). In a follow-up study using the same population, this group confirmed the association 
between the SNP-C allele and JIA and showed that elevated levels of MIF were present in the 
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sera of healthy individuals with the C allele (113). Another study of a juvenile population with 
JIA again demonstrated that those individuals with an SNP-C allele had higher serum and 
synovial fluid MIF levels (114). Additionally, those with at least one SNP-C allele were less 
responsive to steroid therapy. The C allele introduces an activator protein-4 transcription factor-
binding site, which may be responsible for increased MIF levels (115). Study of the functionality 
of the SNP-C allele in vitro by this group yielded contradictory results with increased levels of 
expression found in a T lymphoblast line but decreased levels found in an epithelial cell line. This 
discrepancy could be due to differences in transcription factor binding in different cell lines. 
There is strong linkage disequilibrium between the rare 7-CATT and SNP-C polymorphisms, 
which adds another layer of complexity to the association studies looking at one polymorphism or 
the other. The prevalence of these polymorphisms varies among different populations (116, 117, 
118). As reviewed by Zhong et al., the frequencies of the 5, 6, and 7-CATT alleles in the 
Caucasian population are 27.3%, 60.3%, and 11.0%, respectively. In a healthy African 
population, the frequencies of the 5, 6, and 7-CATT alleles have been reported as 41.3%, 45.0%, 
and 13.0%, respectively. For the SNP, in the Caucasian population, the frequencies are 88.1% for 
the G allele and 11.9% for the C allele. In the African population, the G allele frequency is 38.7% 
and the C allele frequency is 61.3%.  
These two MIF promoter polymorphisms have been studied in a variety of different 
settings and have been associated with a number of human diseases. These studies often analyze 
genotypes in different ways and in varying populations, so it is important to examine the way in 
which the study was conducted. In reviewing these association studies, it becomes clear that there 
is no single clear-cut “inflammatory” genotype associated with all diseases that have been 
studied, but certain patterns have emerged. For example, a Spanish case-control study of 
individuals with erythema nodosum (EN) demonstrated an association between the MIF SNP-C 
allele and EN secondary to sarcoidosis but not other forms of EN (119). In a study of Japanese 
individuals with alopecia areata, the –173-C allele was associated with early onset of severe 
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disease, which had previously been associated with elevated serum MIF (120). Japanese patients 
with either the –173-GC genotype or who had no –794 5-CATT alleles had a greater than 3-fold 
relative risk of atopy, though not asthma, when compared with controls (121). On the other hand, 
a recent study revealed that the 5-CATT allele was associated with lower asthma severity in a 
Caucasian group of patients (122). In a case-control study of Turkish children, higher frequencies 
of the –173-GC and –173-CC genotypes were found in children with idiopathic nephrotic 
syndrome (123). Interestingly, the –173-CC genotype was significantly higher among those with 
steroid-resistant disease. In another study of Japanese subjects, non-carriers of the –794 5-CATT 
allele were more likely to be obese while the –173 genotype did not significantly correlate with 
obesity (124). However, the CATT-5/-173-G haplotype was associated with decreased risk while 
the CATT-6/-173-G haplotype was associated with increased risk of obesity. The –173-CC 
genotype was associated with pancolitis-type ulcerative colitis versus more limited types in a 
population of Japanese patients (125). A case-control study of Caucasian individuals showed an 
association between the CATT-7 allele, -173-C allele, or the CATT-7/-173-C haplotype with 
chronic plaque psoriasis (126). As illustrated by these diverse studies, certain MIF alleles appear 
to be associated with many inflammatory diseases, though the exact role for MIF in pathogenesis 
of disease remains elusive. 
While MIF has a clear role in the immune response to infectious stimuli in experimental 
studies, only recently have published studies begun to link the MIF polymorphisms to infectious 
diseases. A small preliminary study of Zambian children admitted to the hospital with malaria 
demonstrated that individuals with at least one 5-CATT allele had lower parasitemia loads than 
those children with no CATT-5 alleles (127). A case-control study of Irish adults with stable 
cystic fibrosis revealed that individuals with a 5-CATT allele had lower incidence of colonization 
with Pseudomonas aeruginosa, a common respiratory pathogen in this population, but no 
difference in rates of Staphylococcus aureus or Candida albicans carriage (128). It is unclear 
what mechanism underlies these differences. As with inflammatory diseases, the relationship 
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between MIF genetics and infectious disease is not consistent or clear-cut. This is most likely due 
to the complexity of the host-microbe interaction and the potential for multiple contributing 
factors, including host and microbe variation, to disease susceptibility. 
Severe infection with Streptococcus pneumoniae as a model for genetic studies 
Because both sepsis and meningitis can be caused by many pathogens, elucidating the 
precise genetic determinants for these types of infections is difficult. In order to simplify this 
question, it is helpful to pick one particular cause of these syndromes. Infection with 
Streptococcus pneumoniae is a specific example of the complex of interaction between host and 
microbe factors. Streptococcus pneumoniae is a gram positive, aerobic diplococcus that is a very 
common cause of a variety of disease states in the human host, including otitis media, sinusitis, 
bronchitis, pneumonia, bacteremia, and meningitis (129). Pneumococci reside in the nasopharynx 
of many individuals, especially during winter, without causing disease (130). What determines 
whether one person will develop fulminant disease as opposed to occult bacteremia or 
nasopharyngeal carriage is not clear, and it would seem unlikely for the strain of bacteria to fully 
explain the variability. Because of the clinical variation in pneumococcal disease, it is a good 
model to explore genetic polymorphisms that may influence the host response to infection. Two 
vaccines (one polysaccharide and one conjugated) are available for prevention of pneumococcal 
disease, and individuals with polymorphisms that contribute to high risk of invasive disease could 
be candidates for earlier vaccination (131, 132, 133). 
The incidence of pneumococcal disease in 1998 was estimated from a population-based 
surveillance of 9 states to be 23.2 cases per 100,000 people, with higher rates among the very 
young and very old as well as among blacks of all ages (134). Case-fatality was 10% among all 
cases and was highest in the elderly (20.6%) and in those with meningitis (16.7%). In 2002-2003, 
there were an estimated 23,600 cases and 4500 deaths per year in American adults over 50 years 
old, a decrease of 6250 cases and 550 deaths from the 1998 pre-childhood vaccination data (135). 
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The higher rates of pneumococcal disease that have been reported among blacks and native 
Americans could be due in part to higher prevalence of underlying co-morbidities, such as HIV, 
sickle cell disease, and diabetes, or to disparities in vaccination rates (136, 137, 138, 139). Yet, 
these disparities have not been fully examined or accounted for, and the fact that many of the 
genetic polymorphisms show racial and ethnic variation suggests that these may also play a role 
in the different rates of pneumococcal infection among blacks and Native Americans. Currently, 
nothing is known about the prevalence of the MIF polymorphisms in groups of patients with 
these co-morbidities. The incidence of invasive pneumococcal disease rises sharply during the 
winter months, possibly due to a concomitant increase in respiratory viral illnesses (140). Despite 
effective vaccinations, pneumococcal disease remains a significant challenge. 
To fully understand the complexity of pneumococcal disease, the microbe and the host 
need to be examined. Pneumococci have played an important historical role in the discovery and 
elucidation of principles of humoral immunity and of molecular genetics (141). As gram-positive 
bacteria, pneumococci do not act through LPS but instead act via an oligosaccharide capsule, cell 
wall, and surface proteins to gain access into the host and incite an inflammatory response 
through extracellular receptors (142). More than 90 capsular serotypes, each stimulating the 
appearance of specific antibodies, have been identified (143). The cell wall is composed largely 
of peptidoglycan (PGN) and teichoic acid and has a number of associated surface proteins, and 
there is an underlying three-layer cell membrane containing lipids and teichoic acid. 
In order for the pneumococcus to cause disease, it must invade into areas where it does 
not normally inhabit, avoid immune clearance, replicate, and cause tissue damage. Once bound to 
cells by molecules known as adhesins, the bacteria are cleared by, colonize, or invade the host. In 
order to cause disease, the bacteria avoid phagocytosis through multiple mechanisms, including 
the capsule and production of certain toxins, such as pneumolysin. Once the pneumococci have 
invaded, they activate the complement cascade. In addition, peptidoglycan and techoic acid bind 
to toll-like receptor 2 and pneumolysin to toll-like receptor 4 to upregulate proinflammatory 
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cytokine production (144, 145). This inflammatory response is often responsible for the clinical 
disease caused by pneumococci. Individual genetic variability likely plays a role in severity and 
type of invasive streptococcal disease. For instance, certain variants in the MBL gene, which 
activates the complement cascade, correlate with increased susceptibility to invasive infection 
(146). Another study found that certain polymorphisms in IL-10, a key anti-inflammatory 
molecule, were associated with septic shock from pneumococci (147).  
Many other conditions also have been shown to predispose individuals to pneumococcal 
infection (148). Because clearance of the bacteria relies on humoral immunity, any congenital or 
acquired deficiency of antibody production contributes to invasive disease. Other immune 
deficiencies, including complement defects, neutropenia, neutrophil dysfunction, and asplenia, 
also predispose to infection. The increased incidence of Streptococcus pneumoniae infections 
among certain populations, including those with liver disease, pulmonary disease, diabetes, old 
age, viral infections, and alcoholism, is often multifactorial. For instance, older individuals 
produce fewer and faulty immunoglobulins and have poor gag reflexes, many comorbidities, and, 
often, malnutrition. When considered in the context of these diverse bacterial and host factors, 
pneumoccal infection is pathophysiologically complex. Its ability to cause a wide variety of 
clinical syndromes, including sepsis and meningitis, makes it a good candidate infection to 
examine underlying genetic predispositions to particular disease phenotypes. 
SPECIFIC AIMS AND HYPOTHESIS 
This study comprised in vitro and in vivo components. The goals of the in vitro portion 
were to confirm MIF release from monocytic cells stimulated with bacterial products and to 
examine stimulated MIF release from peripheral blood monocytic cells (pBMCs) harvested from 
healthy individuals with varying genotypes. We hypothesized that pBMCs cultured from 
individuals with low-expressing MIF genotypes (5-CATT alleles or SNP-GG) would have less 
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MIF release at baseline or in response to microbial product stimulation than those individuals 
with high-expressing MIF genotypes (7-CATT or SNP-C alleles).  
The goal of the in vivo translational study was to examine whether MIF promoter 
genotypes affect severity and type of invasive pneumococcal disease. Our hypothesis was that 
individuals with the low-expressing MIF genotypes (5-CATT alleles or SNP-GG) would have 
less severe systemic inflammatory responses while individuals with the high-expressing MIF 
genotypes (7-CATT or SNP-C alleles) would have a more severe systemic inflammatory response 
to infection with Streptoccus pneumoniae. 
MATERIALS AND METHODS 
Contributions: The W.M. Keck facility at Yale University ran the DNA fragment analysis assays 
and generated primers for PCR reactions. Members of the Bucala Laboratory carried out 
determination of the healthy control MIF genotypes and generated reagents for the human MIF 
ELISA. The author of this thesis completed all other experiments. A presentation of the 
preliminary data from this report was given at the Infectious Disease Society of America 43rd 
Annual Meeting in October 2005. 
Reagents: LPS from E. coli serotype 011:B4 (Fluka) was resuspended in pyrogen-free water at a 
concentration of 200 μg/ml, aliquoted, and stored at –20˚C. PGN from Staphylococcus aureus 
(Fluka) was resuspended in pyrogen-free water at a concentration of 2 mg/ml, aliquoted, and 
stored at –20 ˚C. 
Cells: All cells were maintained at 37°C in a humidified environment with 5% CO2. THP-1 
human monocytes (American Type Culture Collection) were cultured in Dulbecco’s Modified 
Eagles medium (DMEM, Gibco), which contained 10% fetal bovine serum (FBS, Gibco) unless 
otherwise noted. Peripheral blood monocytes (pBMCs) were purified in a sterile fashion using the 
Ficoll-Paque plus method as follows (Amersham Biosciences). Five ml of venous blood in 1 
mg/ml K2EDTA was collected in Vacutainer tubes (Fisher) from 10 healthy donors with MIF 
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genotypes previously ascertained by members of the Bucala Laboratory. Blood was diluted to 35 
ml with cold phosphate buffered solution (PBS) in a 50 ml conical tube. Fifteen ml of sterile 
Ficoll-Paque Plus was layered at the bottom of each tube with careful maintenance of an intact 
blood:Ficoll interface. Tubes were centrifuged at 1800 revolutions per minute for 30 minutes at 
18○C without brakes. The white blood cell layer was removed from the Ficoll-Paque Plus:plasma 
interface, transferred with a sterile Pasteur pipette to a 15 ml conical tube, and washed twice with 
PBS. For each wash step, tubes were centrifuged at 1800 RPM for 5 minutes at 4○C with brakes, 
and the supernatant was discarded carefully. Cells were resuspended to 105 cells/ml in DMEM 
with 10% FBS, plated in 96-well tissue culture plates (Becton-Dickenson), and cultured 
overnight. The adherent cells were then washed three times with PBS and used for experiments 
described below. For experiments comparing genotypes, these cells were prepared in parallel to 
minimize variation.  
Stimulation of cells with LPS and PGN: THP-1 cells were cultured overnight prior to 
experiments at 5 x 105 cells/ml and plated at 2 x 104 cells/well in 96-well tissue culture plates 
(Becton-Dickenson). THP-1 cells or adherent pBMCs were treated with DMEM + 10% FBS ± 10 
ng/ml-10 μg/ml LPS or 100 ng/ml-100 μg/ml PGN for 6-24 hours. Supernatants from selected 
wells were collected, and cellular debris was centrifuged into a pellet. The supernatants were 
stored in 1.5 ml centrifuge tubes at –20°C until further analysis. Other wells with stimulated 
THP1 or pBMCs were used for LDH assays or lysis studies, as described below. 
Cell lysis: To determine intracellular MIF stores, both THP-1 cells and pBMCs were lysed after 
stimulation with LPS or PGN with a 1:10 ratio of Cell Lysis Solution (Promega) to volume. The 
lysate was centrifuged to eliminate debris, and the supernatants were stored at –20°C until further 
analysis. 
Lactate dehydrogenase (LDH) assay: To examine cell death, CytoTox 96 Non-radioactive 
Cytotoxicity Assays (Promega) were carried out. Cell supernatants were collected at the specified 
time-points. One-hundred μl of supernatant from the above experiments was incubated with 50 μl 
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Substrate Solution for 30 minutes in the dark. The reaction was arrested with the Stop Solution 
and analyzed for colorimetric changes with a spectrophotometer.  
Enzyme-linked immunosorbant assay (ELISA) for detection of MIF: Levels of MIF in cell 
supernatants and in the plasma of subjects were obtained by sandwich ELISA (149). Ninety-six 
well microtiter plates (Nunc) were coated overnight at 4○C with 1 μg/well of mouse monoclonal 
IgG antibody directed against human MIF IgG. Plates were washed 3 times with wash buffer 
containing 0.05% Tween20 (Sigma) in PBS, blotted dry with clean paper towels, and blocked 
overnight at 4○C with 250 μl of buffer containing 1% BSA and 1% sucrose in PBS. Before 
applying samples, the blocking buffer was removed, and plates were blotted dry with paper 
towels. Recombinant human MIF was prepared by serial dilution from 1.6-100 ng/ml for the 
standard curve. The assay was sensitive for concentrations of MIF from 0 to 50 ng/ml. Fifty μl 
sample or standard plus 50 μl of conjugate mouse anti-human MIF-HRP diluted 1:250 in reaction 
buffer containing 1% BSA, 1 mM EDTA, and 0.05% Tween20 (Sigma) in PBS was applied to 
each well. The plate was incubated for two hours in the dark at room temperature and then 
washed 5 times with 250 μl wash buffer. One-hundred μl TMB substrate-chromagen (Dako 
Corporation) was added to each well, and plates were incubated for 30 minutes at room 
temperature in the dark. One hundred μl stop solution containing 2 M H2SO4 and 0.5 M HCl was 
added to each well, and the optical density of each plate was determined with a microplate reader 
set to 450 nm and 590 nm. 
Bradford protein assay: To assess total protein content in pBMCs, Bradford Assays (Bio-Rad) 
were carried out in serum-free conditions. After cell stimulation, adherent cells were washed 
three times with PBS and lysed in a solution of 105 cells/100 μl 0.1% Triton-X (Sigma). Protein 
standards were made with serial dilutions of 1 mg/ml bovine serum albumin (BSA) in water with 
concentrations ranging from 1-10 μg/ml BSA. One to 50 μl of each sample or standard was mixed 
with dH2O to 800 μl and then with 200 μl Bradford Solution. Samples were incubated at room 
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temperature for 5 minutes. Samples were read in triplicate, and absorbance at 595 nm was 
calculated using a spectrophotometer. 
Patient samples: From September 2004 to September 2005, hospitalized patients over 18 years 
of age with positive cultures for Streptococcus pneumoniae isolated from sterile body fluids (e.g. 
blood, CSF, pleural fluid, joint aspirates, peritoneal fluid) were identified through the 
microbiology laboratories at the Hospital of Saint Raphael, Saint Francis Hospital, and Yale-New 
Haven Hospital. Permission to approach the potential subjects for enrollment and assessment of 
capacity to consent was obtained from the attending physician. Written informed consent was 
obtained from all subjects or surrogate decision-makers. The respective hospital investigation 
review boards and the Yale Human Investigation Committee approved the study protocol. Blood 
samples were collected into EDTA-coated Vacutainer tubes (Fisher) from subjects by 
venopuncture or from central lines. Alternatively, blood samples previously collected during the 
hospitalization and stored at 4°C by the hospital chemistry laboratories were obtained. Samples 
were transferred to 15-ml conical tubes and separated by centrifugation for 10 minutes at 2,000 
rpm. Serum and buffy coats were collected and stored at –80○C until further analysis. Certain 
whole blood samples were spotted onto filter paper, dried, and stored at –20○C.  
Data collected: Information from the patient’s admission record, including presenting signs and 
symptoms, physical findings, laboratory and imaging results, and outcomes, was collected onto 
data-extraction forms and entered into Microsoft Excel spreadsheets for statistical analyses. 
DNA extraction: Genomic DNA was isolated per manufacturer protocol from patient serum 
using DNAzol Reagent (Invitrogen) or from dried, whole blood-spotted filter paper using the 
QIAmp DNA Blood Mini kit (Qiagen). Briefly, for the DNAzol protocol, 900 μl of DNAzol 
Reagent was added to 100 μl of patient serum and incubated for 3 minutes at room temperature. 
The DNA was mixed by inversion with 500 μl of 100% ethanol, incubated for 3 minutes at room 
temperature, and centrifuged at 4,000 x g for 1 minute at room temperature to precipitate and 
pellet the DNA. The pellet was then resuspended twice with 1 ml of 70% ethanol. After 
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resuspension, the DNA was re-pelleted at 4,000 x g, and the ethanol was decanted. After the 
second wash, the ethanol was removed by pipette, and the DNA was air dried for 15 seconds in 
an open tube under a fume hood. The DNA was then resuspended with 200 μl of 8 mM NaOH 
and stored at –20°C. For the QIAmp method, Qiagen supplied all reagents. Briefly, the dried 
blood spot from the filter paper was placed into a 1.5-ml microcentrifuge tube with 180 μl of 
Buffer ATL and incubated at 85°C for 10 minutes. Twenty μl Proteinase K stock solution was 
added, vortexed, and incubated at 56°C for 1 hour. Two-hundred μl Buffer AL was added, 
vortexed, and incubated at 70°C for 10 minutes. Two-hundred μl of 100% ethanol was added and 
vortexed. This solution was applied to a QIAamp Spin Column in a 2 ml collection tube and 
centrifuged at 6,000 x g for 1 minute. The column was placed in a new collection tube, 500 μl 
Buffer AW1 was added, and the sample was centrifuged at 6,000 x g for 1 minute. The column 
was placed into another collection tube, 500 μl Buffer AW2 was added, and the sample was 
centrifuged at 20,000 x g for 3 minutes. The column was then placed in a 1.5-ml microcentrifuge 
tube, and 150 μl of dH2O was added. The sample was incubated at room temperature for 1 
minute, and then centrifuged at 6,000 x g for 1 minute, and stored at –20°C. 
Multiple displacement amplification: Genomic DNA was amplified by multiple displacement 
amplification overnight at 31○C in a 99 μl solution containing: 37.5 mM pH 7.5 Tris-HCl, 50 mM 
KCl, 10 mM MgCl2, 5 mM (NH4)2SO4, 1 mM each dNTP, 0.05 mM thiophosphate-modified 
primer (5’-NNNN*N*N, *=phosphorothioate), 0.2 units yeast pyrophosphatase (Roche), 1 unit 
Phi29 polymerase, and 1-5 ng genomic DNA (150). The reaction was stopped at 75○C for five 
minutes, and the product was analyzed on a 1% ethidium bromide-stained agarose gel. 
Fragment analysis protocol for CATT repeat polymorphism: The MIF gene was amplified 
specifically from the genomic MDA products by polymerase chain reaction (PCR) using the 
following reagents: 22.5 μl Invitrogen Supermix, 1 μl dH2O, 0.5 μl CATT forward primer 
(TGCAGGAACCAATACCCATAGG), 0.5 μl CATT reverse primer 
(XAATGGTAAACTCGGGGAC, X=6-FAM label), and 0.5 μl of the DNA product from the 
 27
MDA reaction. The reactions were amplified with the following thermal profile: 1 cycle at 95○C 
for 12 min followed by 40 cycles of 95○C for 30 sec, 54○C for 30 sec, and 72○C for 60 sec, and 
one cycle of 72○C for 10 min. Samples were then cooled to 4○C. To confirm that the amplified 
gene products were the anticipated sizes of 340-352 base pairs, the PCR products were resolved 
on 1.5 % agarose gels stained with ethidium bromide. One μl of each product was then diluted in 
9 μl of dH2O and loaded into a 96-well Applied Biosystems MicroAmp Optical Plate. Samples 
were resolved using an ABI 3730XL DNA Sequencer (Applied Biosystems) with the LIZ500 dye 
size standards. The data was analyzed using Genemapper version 3.7 software (Applied 
Biosystems). 
Single nucleotide polymorphism analysis: DNA from MDA reactions was purified using the 
Qiagen Protocol for Cleanup of Genomic DNA as follows. One hundred μl of genomic DNA, 10 
μl of buffer AW1, and 250 μl of buffer AW2 were mixed by pulse-vortexing and transferred to a 
QIAmp MinElute Column (Qiagen). Each column was centrifuged at 6,000 x g for 1 minute and 
placed in a clean collection tube. Five hundred μl of buffer AW2 was added, and the column was 
centrifuged again at 6,000 x g for 1 minute and placed in another clean collection tube. Each 
column was centrifuged at 20,000 x g for 3 minutes and placed in a clean 1.5 ml microcentrifuge 
tube. Each column was eluted with 20 μl of buffer AE for one minute and then centrifuged at 
20,000 x g for one minute. The concentration of DNA was calculated using the 260/280 
spectrophotometer absorbance ratio. DNA was diluted in dH2O to 5 ng/μl. For the allelic 
discrimination PCR reaction, the following components were combined: 2.5 μl 2X TaqMan 
Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems), 0.25 μl 20X Assays-On-
Demand SNP Genotyping Assay Mix for the MIF –173 G/C SNP (Applied Biosystems), and 2.25 
μl genomic DNA diluted to 5 ng/ml. Samples were loaded into 384 well clear optical reaction 
plates (Applied Biosystems) and covered with optical adhesive covers (Applied Biosystems). The 
PCR reaction was completed at the Yale University Keck Affymetrix Facility using an ABI Prism 
7900 machine. The reaction parameters were: 1 hold cycle for 10 minutes at 95°C followed by 45 
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cycles of denaturation for 15 seconds at 92°C and annealing/extension for 1 minute at 60 °C. The 
alleles were analyzed with SDS v2.2 software. 
Disease type classification: Pneumonia was classified based on clinical diagnosis as documented 
in the patient’s medical record, which included physical exam and chest radiography findings. 
Classification of a case as meningitis was based either on positive pneumococcal cultures grown 
from the CSF or from charted clinical signs and symptoms consistent with meningitis plus 
positive blood cultures and a lumbar puncture demonstrating pleocytosis with predominance of 
neutrophils, high protein, low glucose, and high opening pressure. 
Disease severity classification: The diagnosis of the severity of infection was based on the 
consensus criteria for the systemic inflammatory response syndrome and sepsis published by the 
American College of Chest Physicians (151). Sepsis was defined if the subjects with documented 
invasive S. pneumoniae had at least two of the following abnormalities: temperature > 38 ○C or < 
36 ○C; heart-rate > 90 beats/minute; respiratory rate > 20 breaths/minute or PaCO2 < 32 mmHg; 
white blood-cell count > 12,000 cells/mm3, < 4,000 cells/mm3, or > 10% immature band forms. 
Severe sepsis involved sepsis plus evidence of end-organ damage. Because only clinical data 
from time 0 was collected, it was not possible to identify those with septic shock refractory to 
resuscitation efforts, which requires ongoing data. Those individuals with shock at time 0 were 
placed into the severe sepsis category. For this study, the definition of end-organ damage 
included but was not limited to: systolic blood pressure (SBP) < 90 or mean-arterial pressure 
(MAP) < 70 or need for pressors for > 60 minutes; urine output < 0.5 cc/kg body weight for > 60 
minutes; PaO2/FiO2 < 250; platelets < 80,000 cells/mm3 or decrease by more than 1/3; pH < 7.30 
and lactate > 1.5x upper limit of normal. Evidence of meningitis was included in the definition of 
end-organ damage, and these individuals were placed in the severe sepsis category. The author of 
this study was blinded to MIF genotype when assignments of disease severity were made. 
Statistical analysis: The data were analyzed using GraphPad Prism software (GraphPad 
Software) and Microsoft Excel (Microsoft). Data are presented as mean ± SD for all experiments. 
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Differences between two means were calculated using independent two-tailed t-tests. 
Distributions were presumed to be normal unless noted in the text. For the comparison of mean 
MIF levels in subjects with pneumococcal infections, a normal distribution was defined as a 
skewness that was not more than twice the standard error for skewness. Differences between 
more than two means were tested using a one-way analysis of variance (ANOVA) test with post-
test analysis by Tukey test. The relationship between genotype and disease type or severity was 
examined using the Fishers’ exact test for contingency tables containing small numbers. A p-
value less than 0.05 was taken as significant. Because this was an exploratory study, no 
assumptions about power were made prior to completion. 
RESULTS 
MIF release from THP-1 monocyte cells stimulated with LPS and PGN 
Previous studies have shown that macrophage cell lines release MIF when stimulated with LPS 
(152). To confirm these results, THP-1 cells, a monocytic cell line population, were incubated with varying 
concentrations of LPS for 6-24 hours, and MIF release was determined by ELISA assay. Data are not 
shown for various time points because the 6-hour incubation yielded the most MIF release with the least 
cell death as seen under the microscope. As shown in Fig. 1, the optimal release of MIF occurred with an 
LPS concentration of 10 μg/ml for 6 hours. Lower concentrations of LPS did not yield MIF release. Figs. 2 
and 4 show further experiments confirming MIF release from THP-1 cells treated with 10 μg/ml LPS for 6 
hours. This LPS concentration was significantly higher than the dilutions used in the first report of LPS-
stimulated MIF release by Calandra and colleagues. In that study, MIF release was measured by Western 
blot from RAW 264.7 macrophages with as little as 10 pg/ml LPS, peaked at 1 ng/ml, and was not 
observed at LPS concentrations greater than 1 μg/ml. The results from that study may have differed from 
those observed in the experiments discussed above because MIF release was measured in a different, less 
objective manner and because a different cell line was used. In this study, MIF was released in significant 





















Figure 1. THP1 cells treated with varying concentrations of LPS. Each column represents the mean ± 
SD of three wells. *One-way ANOVA, p = 0.007. Significant differences (p < 0.05) were seen for 
untreated vs. 10 μg/ml LPS-treated cells; 1 μg/ml vs. 10 μg/ml LPS-treated cells; and 10 ng/ml vs. 10 μg/ml 
LPS-treated cells; and between 100 ng/ml vs. 10 μg/ml LPS-treated cells at a significance of p < 0.01.  
 To assess cell membrane integrity, lactate dehydrogenase (LDH) assays were performed 
(Figs. 3, 5). Because this enzyme is constitutively expressed in all cells, and cell death induces 
enzyme release, the presence of LDH indicates cell death. The THP-1 cells treated with LPS 
showed significantly higher levels of cell death when compared with the untreated cells in some, 
though not all, experiments (Figs. 3, 5). The increased MIF measured in the supernatants of those 
cells treated with LPS, thus, may have been partially due to cell death. Since MIF is stored in 
preformed pools in cells, cell death will lead to elevated MIF in cell supernatants. However, even 
in the experiments where LPS-treatment did not lead to increased cell death (Figs. 4 and 5), there 
was still significant MIF found in the supernatants, indicating that MIF release from pre-formed 
pools in living cells is also likely a contributor to increased cytokine levels. 
 To explore the effect of gram-positive cell walls on monocyte MIF release, PGN at 
concentrations of 100 ng/ml to 100 μg/ml was used to stimulate THP-1 cells. PGN-treated cells 
did not release significantly higher amounts of MIF than untreated cells at any concentration (Fig. 
4). The LDH assays for this experiment demonstrate that PGN did not induce cell death (Fig. 5). 
The concentration of PGN was similar to that used in previously published monocyte stimulation 
*
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Figure 2. MIF release from THP-1 cells treated with LPS. 10 μg/ml LPS was applied for 6 hours. Each 
column represents the mean ± SD of three wells. Each experiment was repeated at least three times. *T-test, 












Figure 3. Cell integrity of THP-1 cells treated with LPS. Cell integrity was measured by LDH release. 
Each column represents the mean ± SD of three wells. Each experiment was repeated at least three times. 























Figure 4. MIF content and release from THP-1 cells treated with LPS or PGN. Cells were stimulated 
for 6 hours with LPS (10 μg/ml) or PGN (100 μg/ml) Each column represents the mean ± SD of three 
wells. Each experiment was repeated at least three times. *T-test, p = 0.0120 for MIF release from LPS-


















Figure 5. Cell integrity of THP-1 cells. Cell death measured by LDH release. Each column represents the 
mean ± SD of three wells. Each experiment was repeated at least three times. T-test, p = 0.5332 for LDH 
release from untreated vs. LPS-treated cells. T-test, p = 0.8490 for PGN-treated vs. untreated cells. 
Basal serum MIF levels from healthy individuals with different MIF genotypes 
 Afternoon serum MIF levels were measured by ELISA from healthy control pBMC 
donors with known MIF CATT-polymorphism genotypes. For each individual, alleles are 
numbered 5-8, depending on the number of CATT repeats, and genotypes are listed as two 
*
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numbers, indicating the repeats present on each allele. The SNP–173 genotypes for these 
individuals was not known. As shown in Fig. 6, the mean serum MIF levels between individuals 
did not show a perfectly reliable pattern. However, a one-way ANOVA test revealed that there 
were significant differences between several of the samples (see Fig. 6), indicating that the 5-
allele containing genotypes in general secreted lower levels of MIF than the non-5 containing 
genotypes. Though the sample size was very small, this suggestive trend is consistent with 
published data indicating increasing serum MIF levels with increasing numbers of CATT repeats 
(155). The CATT-5,5 #1 sample had slightly higher MIF release than would be expected if there 
were a completely linear relationship between CATT repeats and MIF release. Yet, since each 
column represents only one person, variation between individuals may have accounted for this 
deviation. The fact that CATT-5,5 #2 sample did not show this elevation supports this idea of 
individual differences. The existence of individual variation in MIF release based on genotype is 


















Figure 6. Basal afternoon serum MIF levels from individuals with known CATT genotypes. Each 
column represents an individual with two CATT alleles (5-8) separated by commas and is the mean ± SD 
of three wells. One-way ANOVA, p < 0.0001. Differences are significant (p < 0.05) for: 5,5 #1 vs. 5,6; 5,5 
#1 vs. 6,7; 5,5 #2 vs. 6,6; 5,5 #2 vs. 6,7; 5,6 vs. 6,6; 5,6 vs. 6,7; 6,6 vs. 6,7. 
#1 #2 
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MIF release and storage in unstimulated pBMCs from individuals with different genotypes 
Blood was drawn from healthy controls with known –794 CATT genotypes, and pBMCs 
were purified by Ficoll gradient. For each experiment, blood was drawn from all subjects at the 
same time of day to avoid circadian variation in MIF expression and release. After purification, 
the pBMCs were lysed, and MIF content was determined by ELISA. To standardize for overall 
cellular transcription activity, MIF content was normalized to total protein content as determined 
by Bradford assay. As shown in Fig. 7, there were no significant differences in MIF-to-total 
protein content ratios in pBMCs from individuals with different CATT genotypes (one-way 
ANOVA, p = 0.7839). These experiments were repeated multiple times with significant intra-
individual variation. 



















Figure 7. Basal MIF stored in pBMCs from individuals with different CATT genotypes. MIF protein 
levels are normalized to total cell protein levels. Each column represents one individual with two CATT-
alleles separated by commas (5-8). Each point signifies one experiment and represents the mean of three 
wells. The horizontal lines represent means of all points in a column. One-way ANOVA p = 0.7839. 
Basal MIF release was determined from supernatants of the adherent pBMCs from 
healthy individuals cultured overnight. As shown in Fig. 8, mean basal MIF release did not differ 
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between individuals with various CATT genotypes (one-way ANOVA, p = 0.8460). There was 
great variation in basal MIF release for all individuals between experiments, which may have 
masked any differences. LDH assays were not completed, so it is not known whether the 
differences between individual MIF supernatant levels is due to variation in cell death rates or 
variation in secretion. 













Figure 8. Basal MIF released from pBMCs from individuals with different CATT genotypes. Each 
column represents one individual with two CATT-alleles separated by commas (5-8). Each point signifies 
one experiment and represents the mean of three wells. The horizontal lines represent means of all points in 
a column. One-way ANOVA p = 0.8460. 
MIF release from pBMCs stimulated with LPS 
 Adherent pBMCs were stimulated with 10 μg/ml LPS for 6 hours, and MIF release was 
measured from cell supernatants by ELISA. As shown in Fig. 9, there were no significant 
differences in stimulated MIF release according to genotype (ANOVA, p = 0.3409). Again, MIF 
release varied dramatically between experiments, indicating that intrinsic variations may mask 
any effect of CATT genotypes. Because these studies relied on pBMCs taken from individuals 
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over several different time points, it is likely that many other host factors contributed to the level 
of response of the cells. Such factors could include the level of stress, which would alter 
endogenous corticosteroids, or the possibility of sub-clinical infections, which could affect the 
responsiveness of cells. In addition, LDH assays were not performed for these pBMC 
experiments, so disparities in levels of cell death in response to LPS may have contributed to the 
wide deviations. Furthermore, because the sample size was small, individual variation in LPS-
stimulated MIF release could have be due to multiple other factors, such as TLR4 polymorphisms 
or concomitant stress leading to differing corticosteroid levels. 














Figure 9. MIF released from pBMCs of individuals with different genotypes stimulated with LPS. 
Cells were stimulated by 10 μg/ml LPS for 24 hours. Each column represents one individual with two 
CATT-alleles separated by commas (5-8). Each point signifies one experiment and represents the mean of 
three wells. The horizontal lines represent means of all points in a column. One-way ANOVA p = 0.3409. 
Patient enrollment and baseline characteristics 
Between September 2004, and September 2005, 68 patients over the age of 18 with 
invasive S. pneumoniae infections were admitted to the three participating hospitals and were 
eligible for enrollment based on age and microbiological data (Fig. 10). Patients were required to 
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be in the hospital at the time of consent. Of these 68 patients, 36 individuals died or were 
discharged home before their microbiological cultures grew colonies and, thus, they could not be 
identified and enrolled while still hospitalized. Thirty-two eligible patients or their representatives 
were approached, and 30 individuals consented to be a part of this observational study. 
 
Figure 10. Patient enrollment. Eligibility was determined if individual was at least 18 years old, had 
microbiological cultures from a normally sterile site that grew S. pneumoniae, and were in the hospital at 
time of consent. 
   Baseline characteristics for enrolled subjects are shown in Table 1 and Fig. 11. The high mean 
heart rate, respiratory rate, and white blood cell count indicate the systemic response to the invasive 
bacterial infection. The ethnic/racial distribution reflects the diversity of the communities serviced by the 
participating hospitals in New Haven and Hartford. Clinical characteristics were recorded as the value 
closest to the time of antibiotic administration (defined as time 0). Sources of infection based on culture 
results and clinical data (signs, symptoms, laboratory values, imaging) are shown in Table 2. Not 
surprisingly, pneumonia was the most common source of infection, occurring in 80% of subjects. All 
patients with pneumonia also had positive blood cultures, and 3/30 (10%) had both meningitis and 
pneumonia. Presenting signs and symptoms are shown in Table 3. Clinical data were recorded closest to 
68 patients eligible 
32 patients/representatives approached 
30 patients enrolled 
36 patients died or were discharged 
before cultures grew bacteria 
2 patients declined consent 
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time 0 and were assumed normal if not recorded in the medical record. The most common presenting 
features were consistent with the frequent diagnosis of pneumonia and included cough/sputum production 
(73%), dyspnea/shortness of breath (63%), abnormal lung exam (63%), and new chest radiograph 
abnormalities (77%). Non-specific characteristics, such as fevers/chills (73%) and fatigue (53%), were also 
common.  
Using the American College of Chest Physicians/Society for Critical Care consensus 
definitions, subjects were grouped according to severity of infection at time 0 (156). Five subjects 
(17%) with bacteremia did not meet the systemic inflammatory response syndrome criteria for 
sepsis. Because the numbers in this study were small, these subjects were grouped with simple 
sepsis subjects for most analyses. Ten subjects (33%) mounted a simple septic response without 
end-organ damage, and 15 (50%) had severe sepsis with evidence of end-organ damage. 
Individuals with septic shock were recorded as severe sepsis because data was recorded from one 
point in time (time 0), so the determination of whether the hypotension was responsive to fluids 
over time could not be made. Two of the subjects (7%) died during their hospitalization. 
Table 1. Baseline Characteristics. * 
Female gender—no. (%) 14 (47) 
Age—years 62 ± 17 
Mean arterial pressure—mmHg 79 ± 17 
Heart rate—beats/min 102 ± 20 
Respiratory rate—breaths/min 24 ± 8 
White blood cell count—cells/mm3 27 ± 48 




Figure 11. Race/ethnicity of enrolled subjects. 
 
Table 2. Source of infection. 
Bacteremia without a focus—number (%) 2 (7) 
Pneumonia 21 (70) 
Meningitis  2 (7) 
Pneumonia + meningitis 3 (10) 
Other focus 2 (7) 
 
Table 3. Presenting signs and symptoms.  
Subjective fevers/chills—no. (%) with sign/symptom 22 (73) 
Night sweats 2 (7) 
Fatigue 16 (53) 
Weakness 14 (47) 










Myalgias 10 (33) 
Headache 6 (20) 
Neck stiffness 3 (10) 
Neurologic symptoms 1 (3) 
Photophobia 0 
Chest pain/pressure/tightness 13 (43) 
Cough/sputum production 22 (73) 
Dyspnea/shortness of breath 19 (63) 
Nausea/vomiting/abdominal pain 13 (43) 
Urinary symptoms 3 (10) 
Altered Mental status 7 (23) 
Lethargy 6 (20) 
Disorientation 3 (10) 
Abnormal lung exam  19 (63) 
New chest radiograph abnormality 23 (77) 
New head CT abnormality 5 (17) 
 
MIF levels in patients with invasive Streptococcus pneumoniae infection 
Serum MIF levels collected upon patient enrollment were measured by ELISA. The mean 
MIF level for all subjects was 20.4 ± 13.13 ng/ml (range = 5-48 ng/ml). The distribution of the 
MIF levels of this population was confirmed normal with a test for skewness (skewness = 0.533, 
standard error of skewness = 0.434). This mean is significantly higher than the normal reported 
values of 1.8-4.5 ng/ml (T-test of the mean normal MIF value versus the mean MIF value for 
subjects with invasive pneumococcal disease, p < 0.0001) (157). Individuals with bacteremia 
were grouped with individuals with simple sepsis for analysis. As discussed above, septic shock 
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patients were categorized as severe sepsis. MIF levels did not differ significantly between disease 
severity categories (p = 0.8977), CNS invasion (p = 0.5201), SNP-173 genotype (p = 0.9370), 



















Figure 12. MIF levels and severity of infection. Serum MIF levels were measured from individuals with 
invasive pneumococcal infections by ELISA. Individuals were grouped by severity of disease. Columns 




















Figure 13. MIF levels and type of infection. Serum MIF levels were measured from individuals with 
invasive pneumococcal infections by ELISA. Individuals were grouped by whether the infection invaded 
the CNS space. Columns represent means ± SD of 3 measurements. T-test, p = 0.5201 for differences in 




















Figure 14. Serum MIF levels and SNP–173 genotype.  Each column contains genotypes with two alleles 
(G or C). Columns represent means ± SD of 3 measurements. ANOVA, p = 0.9370 for differences in MIF 





















Figure 15. Serum MIF levels and 5-CATT genotype.  Each column contains genotypes with two alleles, 
either 5 or X. X = 6, 7, or 8-CATT repeats. Columns represent means ± SD of 3 measurements. T-test, p = 




















Figure 16. Serum MIF levels and 7-CATT genotype.  Each column contains genotypes with two alleles, 
either 7 or Y. Y = 5 or 6-CATT repeats. Columns represent means ± SD of 3 measurements. T-test, p = 
0.2723 for differences in MIF level with CATT-7 allele. 
SNP genotypes and disease severity 
The distribution of SNP–173 genotype and disease severity is shown in Table 4. For the –
173 polymorphism, each allele is listed as a G or a C. The genotype is listed as two letters, 
indicating the two alleles for that individual. The wild-type GG genotype accounted for 65% of 
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individuals with bacteremia/simple sepsis and for 91% of individuals with severe sepsis. Though 
these numbers suggest that the variant C allele, which has been associated with higher MIF 
levels, may offer some protection against severe response to pneumococcal infection, statistical 
tests did not bear out this result (Fishers’ exact test, p = 0.1914). 
Table 4. SNP –173 genotype and disease severity 
 GG—no. (%) GC or CC 
Bacteremia/Simple sepsis 11 (65) 6 (35) 
Severe sepsis 10 (91) 1 (9) 
SNP genotypes and CNS disease  
The distribution of SNP-173 genotype and pneumococcal CNS invasion is shown in 
Table 5. The wild-type GG genotype made up 78% of individuals without meningitis and 60% of 
individuals with meningitis. There were no statistical associations between genotype and 
meningeal infection (Fishers’ exact test, p = 0.5737). 
Table 5. SNP-173 Genotype and CNS infection. 
 
GG—no. (%) GC or CC 
No meningitis 18 (78) 5 (22) 
Meningitis 3 (60) 2 (40) 
CATT genotypes and disease severity 
The distribution of the CATT repeat genotypes and disease severity is displayed in Table 
6. Each allele is labeled from 5-8, depending on the number of CATT repeats. Genotypes are 
expressed as two alleles, separated by commas. There were a variety of genotypes represented. 
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The most common genotype in both groups was the 6,6-CATT repeat genotype, representing 
47% of the bacteremia/simple sepsis group and 60% of the severe sepsis group. These can be 
compared with a series of control genotypes that have previously been completed in our 
laboratory in which the two most common groups are the 6,6-repeat (32%) and the 5,6-repeat 
(36%) genotypes (Fig. 17). Though the distributions of the genotypes of the pneumococcal 
samples differ from the control samples, it is difficult to draw any conclusions since the sampled 
populations are ethnically different.  
As shown in Table 7, there was no association found between genotypes containing a 5-
CATT allele, which is a lower MIF-expressing allele, and disease severity. In the healthy control 
group, 50% of individuals had a 5-CATT allele whereas 40% of those with pneumococcal 
bacteremia/simple sepsis and 33% of those with severe sepsis had this allele. There was also a 
lack of association between genotypes containing the 7-CATT allele, which has been associated 
in many prior studies with disease severity or susceptibility, and disease severity in this study 
(Table 8). In the healthy control group, 24% of individuals had a 7-CATT allele in their 
genotypes while 13% of both groups of sepsis severity had this allele. 
Table 6. MIF CATT genotypes and severity of infection. 
Studied Group 5,5 5,6 5,7 5,8 6,6 6,7 6,8 7,7 7,8
Bacteremia/simple sepsis—no. (%) 3(20) 3(20) 0 0 7(47) 1(7) 0 1(7) 0 


















Figure 17. Distribution of a series of 168 control genotypes. Genotypes come from Caucasian 
individuals chosen as healthy controls for genotyping studies. 
 
Table 7. Lack of association between 5-CATT alleles and disease severity. X = 6, 7, or 8 
allele. p = 1.000. 
 55 or 5X—no. (%) XX 
Bacteremia/Simple sepsis 6 (40) 9 (60) 
Severe sepsis 5 (33) 10 (67) 
 
Table 8. Lack of association between 7-CATT allele and disease severity. Y = 5, 6, or 8 
allele. p = 1.000. 
 YY—no. (%) 77 or 7Y 
Bacteremia/Simple sepsis 13 (87) 2 (13) 
Severe sepsis 13 (87) 2 (13) 
 47
CATT genotypes and CNS disease 
The distribution of CATT genotypes in CNS infection is shown in Table 9. As shown in 
Table 10, there was no association found between the CATT-5 allele and bacterial invasion of the 
CNS by the pneumococci (p = 0.3268). There was a trend suggestive of a possible association 
between the 7-CATT allele and CNS infection, but this did not reach statistical significance 
(Table 11, p = 0.1188). Using these numbers, there was a relative risk of meningitis in genotypes 
containing the 7-CATT allele of 1.5 (95% CI, 0.74-3.2).  
 
Table 9. MIF CATT genotypes and type of infection. 
Studied Group 5,5 5,6 5,7 5,8 6,6 6,7 6,8 7,7 7,8 
No meningitis—no. (%) 4(16) 4(16) 0 0 15(60) 1(4) 0 1(4) 0 
Meningitis 1(20) 1(20) 1(20) 0 1(20) 0 0 1(20) 0 
 
Table 10. Lack of association between 5-CATT alleles and disease type. X = 6, 7, or 8 allele. 
p = 0.3268. 
 55 or 5X—no. (%) XX 
No meningitis 8 (32) 17 (68) 
Meningitis 3 (60) 2 (40) 
 
Table 11. Trend towards association between 7-CATT allele and disease type. Y = 5, 6, or 8 
allele. p = 0.1188. 
 YY—no. (%) 77 or 7Y 
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No meningitis 23 (92) 2 (8) 
Meningitis 3 (60) 2 (40) 
DISCUSSION 
 This project explored the relationship between infectious stimuli, especially gram-
positive infections, and MIF expression using both in vitro and in vivo approaches. The data 
presented herein support a role for MIF in the innate immune response to infection, although the 
details of this cytokine’s actions need to be elucidated. Key findings of our studies were as 
follows. Stimulation of THP-1 monocytes with LPS confirmed induction of MIF expression, but 
this occurred at much higher levels than previously published (158). The reason for this 
difference may be related to the state of activity of the monocytic cells prior to stimulation. In this 
study, the confluence of the cells before LPS addition affected the amount of MIF released (data 
not shown), and it is possible that this contributed to the incongruity with prior reports. Part of the 
LPS-induced release of MIF in this study may have been due to increased cell death in the THP-1 
cells at such high concentrations, which was seen inconsistently with LDH assays. Cell death was 
not measured in prior reports of LPS stimulation of MIF release, so it is unclear what role this 
played in prior studies. Regardless, MIF surely is involved in the response to gram-negative 
bacteria, as shown in this study and many previous reports. The function of MIF in gram-positive 
infections is less apparent.  
Despite earlier data supporting a role for MIF in gram-positive infections, PGN 
stimulation of THP-1 cells did not lead to MIF release in this investigation. The absence of an 
MIF response may be due in part to the lack of cell death in PGN-treated cells but may also 
indicate that gram-positive bacterial products act through different mechanisms than gram-
negative organisms and, thus, result in different cytokine expression profiles. PGN has been 
shown to act via TLR2, but the role of MIF in TLR2 activation has not been well documented 
(159). It is possible that MIF release occurs with some gram-positive bacterial products, such as 
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exotoxins, but not in response to others, such as PGN. Further work with PGN, teichoic acid, and 
whole gram-positive bacteria needs to be completed both in cell cultures and in mouse models in 
order to fully elucidate the role of MIF in gram-positive infections. 
 Much remains to be investigated concerning MIF promoter polymorphisms as well. In 
the studies of healthy controls with various MIF CATT genotypes, there were no differences 
found between genotypes and basal or stimulated pBMC MIF content or release. Reporter assays 
have shown sequential increases in MIF release with increasing CATT repeats, and serum 
samples from individuals with known CATT genotypes in this study showed lower MIF 
expression with 5-CATT allele-containing genotypes (160). However, these results have not been 
reproduced with ex vivo cells, and the pBMC experiments described above did not confirm the 
findings of prior studies correlating repeat number and MIF levels. There was significant 
variation between experiments, and this variation may have masked any trend in MIF expression 
based on genotype. In addition, the series of experiments with pBMCs was based on a small 
number of healthy control individuals, and more individuals may be required to see true 
differences between genotypes. 
To examine the role of MIF polymorphisms in vivo, samples were collected from 
individuals with invasive S. pneumoniae infections. Morbidity and mortality from pneumococcal 
infections are due in part to cytokine activation, and the role for MIF in this infection has not 
been explored (161). Because it is not clear why some individuals experience fulminant 
infections with this bacterium while others are asymptomatic carriers and because it is a cytokine-
mediated disease, pneumococcal infection is a good model in which to study MIF 
polymorphisms. In addition, since vaccines for prevention of invasive pneumococcal infection 
exist, identification of another target population at high risk for infection could help to prevent 
infections (162). As previously reported in the literature with general sepsis and inflammatory 
states, MIF levels in pneumococcal infections were elevated across all genotypes in this study 
(163). MIF levels did not differ by genotype in this study, though. This may be due to the fact 
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that serum was collected from patients at different time points of their hospital stays, depending 
on when their microbiological cultures grew bacteria. Because those subjects who were in the 
more acute stages of illness likely had higher MIF levels, the discrepancy in dates of blood draw 
may have masked any differences between genotypes. The blood was also drawn at different 
times of day, though the importance of circadian release of MIF in acute stress situations is not 
well studied.  
There have not been previously published research examining MIF levels in various 
genotypes during infection, so the differences in protein level that occur at baseline may be 
minimized during the acute increase in MIF across all genotypes. However, the increase in 
susceptibility to infections in cystic fibrosis and malaria patients based on MIF polymorphisms 
argues for an influence of genotype on MIF release or function (164, 165). If all genotypes truly 
did secrete the same amount of MIF during infection, presumably the polymorphisms should not 
have shown an association with infections. However, the lack of differences in protein levels 
despite a positive association could also indicate that the polymorphism is linked to another locus 
that plays a functional role. Yet, studies of the MIF polymorphisms in rheumatologic diseases 
also support the idea that even during active inflammatory states, there is variation in MIF 
expression based on genotype (166, 167). These differences may only be seen at certain time 
points in the infection or may only be evident at the outset of infection. 
Neither of the MIF polymorphic sites had an effect on severity of pneumococcal infection 
in this study. However, because the sample size was so small, this lack of influence is not certain. 
A larger study will need to be carried out in order to state definitively that there are no differences 
between MIF genotypes and severity of pneumococcal disease. In addition, because enrollment in 
this study required both positive microbiological proof of infection and inpatient status, it selected 
for individuals with moderately severe infections. Those with fulminant infections often died 
before their cultures grew out pneumococcus, and those with mild infections were often 
discharged on oral medications. As a result, the spread of severity of disease was likely limited, 
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which possibly masked differences in disease severity seen with MIF genotype. Because there are 
so many differences between various ethnic and racial groups, the diversity of the enrolled 
subjects likely restricted the ability for this study to elucidate differences based on genotype alone 
rather than other factors. A future study controlling for these limitations may help to elucidate the 
role of MIF polymorphisms in severity of pneumococcal disease. 
There was a suggestive trend towards a higher proportion of pro-inflammatory 7-CATT 
alleles in the meningitis population, although the sample size with CNS infection was very small. 
Because the number of meningitis cases in this study was limited, a larger population will need to 
be studied before any conclusions can be made about the pro-inflammatory CATT allele and 
meningitis. A sample size of 118 (98 bacteremia, 20 meningitis) would be needed to detect a 30% 
difference in high-expressing 7-CATT allele-containing genotypes with a power of 80% at a 
significance of 0.05. This trend would have interesting implications for meningitis pathogenesis if 
it proves to be true. It may be that the more inflammatory genotypes allow for increased 
expression of adhesion molecules in the cerebral vascular endothelium or allow for more 
leakiness in the blood-brain barrier. MIF has been shown to upregulate intracellular adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in animal models of 
inflammatory disease (168, 169). Those with higher amounts of MIF may have higher levels of 
adhesion molecule expression, which potentially could allow for more bacteria and inflammatory 
cells to pass into the CSF space. Pneumococci are thought to traverse the blood-brain barrier by 
adhering to and then traversing the endothelial cells (170). In addition to allowing bacteria 
through, increased adhesion molecules allow for more leukocytes to cross the blood-brain barrier 
and contribute to the inflammatory response. 
The argument for a role of cytokine polymorphisms in cerebral infectious diseases is not 
a new one. For instance, homozygosity for the TNF2 allele, the promoter polymorphism 
associated with higher TNF-α expression, has been associated with a 4-fold risk of cerebral 
malaria and a greater than 7-fold risk of death or neurological sequelae from the cerebral 
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infection in Gambian children (171). The authors of this study postulate that the high levels of 
TNF-α expression may increase cerebral disease by increasing endothelial adhesion molecules, 
thus allowing parasites to cross the blood-brain barrier, or by increasing nitric oxide, which could 
inhibit neuronal transmission (172, 173).  
There appears to be a role for adhesion molecules in bacterial meningitis as well as 
parasitic infections. For instance, one study of the CSF of children with and without bacterial 
meningitis demonstrated elevated levels of soluble ICAM-1 in the infected group (174). Though 
the study does not prove pathogenesis, the association is intriguing because meningitis is an 
inflammatory disease where cellular mediators cross the blood-brain barrier. Several animal 
studies also support the idea that adhesion molecules contribute to meningeal inflammation. In a 
rabbit model of meningitis, animals treated with anti-CD18 monoclonal antibodies, which prevent 
leukocyte adhesion, were injected intra-cisternally with whole bacteria or cell walls and were 
found to have less cerebral edema and blood brain barrier injury (175). Specifically, this antibody 
prevented cerebral edema and mortality after injection of a normally lethal dose of Streptococcus 
pneumoniae bacteria. In a mouse model of cytokine-induced meningitis, deficiency of selectins, 
which are important for leukocyte rolling and extravasation, led to decreased CSF leukocytosis 
and blood brain barrier permeability (176). The results from these animal studies suggest that 
adhesion molecule expression is an integral part of the development of bacterial meningitis. The 
activation of such molecules by MIF could provide a mechanism by which increased MIF levels 
contribute to increased risk of meningeal disease. 
If further studies confirm that genotypes leading to elevated MIF levels do indeed 
contribute to susceptibility to meningitis, there could be many other additional reasons why this is 
the case. As discussed above, MIF plays many upstream pro-inflammatory and steroid-regulatory 
roles. The alteration of any or all of these factors could be the contributing cause of meningitis. 
For example, MIF increases expression of matrix metalloproteinases, and these molecules have 
been linked to blood-brain barrier disruption and neuronal injury in animal models of meningitis 
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(177). Nearly any of the pro-inflammatory effects of MIF could be the contributors to meningitis 
susceptibility, and it may be that this cytokine has multiple effects leading to vulnerability. In 
order to elucidate this pathogenesis, animal knockout models will be required to unravel which 
aspects of the inflammatory cascade are important. 
 There were several flaws in the design of the in vivo portion of this study that may have 
contributed to the non-significant findings. First, there was no contemporaneous control group. 
An ideal control population may have been racially/ethnically-matched individuals who were 
admitted to the hospital with fever but no positive blood cultures or racially/ethnically-matched 
healthy control individuals. A second weakness was that the population for this study was 
ethnically and racially heterogeneous, which is in contrast to other studies examining differences 
in expression of genotypes discussed in the Introduction. These studies generally have shown that 
different ethnic groups have distinct genotype distributions (178). Third, because this was a pilot 
study, the population for this project was small. In order to power this study to find a difference 
between genotypes, more than 100 subjects would need to be enrolled. The effect of sample size 
was especially important for the population with meningitis because there were only 5 subjects 
enrolled during the study period. Fourth, as discussed above, the design of this study selected for 
individuals with moderately severe disease and excluded those with fulminant or mild disease. 
Allowing posthumous collection of patient samples as well as enrollment of discharged patients 
would have helped to eliminate this type of bias. Alternatively, enrolling patients upon admission 
prior to getting positive culture results would allow for sample collection from a group of patients 
with a broader spectrum of disease severity. Another limitation was the assumption that values 
that were not recorded in the medical record were normal. This supposition about missing data 
could create both false positive or false negative associations. Finally, as discussed above, the fact 
that patients were enrolled at different points in their hospital stays likely affected the measured 
MIF protein levels and may have concealed any differences between genotypes.  
 54
In summary, this pilot study of MIF promoter polymorphisms and S. pneumoniae 
infections points to a potentially intriguing link between MIF and CNS infections. These results 
need to be expanded upon with further research. In addition to enrolling additional patients with 
pneumococcal infections, animal models will likely also continue to prove a useful tool for 
exploring the role of MIF in gram-positive CNS infections. Moreover, in diseases that have a 
complex genetic basis, it is likely that multiple polymorphisms come together to cause 
susceptibility for a particular individual. For instance, the TLR2 gene contains a polymorphism 
that results in an amino acid substitution and renders cells more responsive to bacterial peptides 
(179). Individuals with this polymorphism may be more susceptible to gram-positive infections. 
If an individual with this TLR2 polymorphism also had polymorphisms causing increased 
expression of TNF-α and MIF, one could imagine a scenario where this unique genetic 
combination of would result in more widespread inflammation and organ damage in the setting of 
a gram-positive infection. This is a simplified example of the multitude of polymorphisms that 
have been associated with disease. In the future, individuals with certain genetic profiles will be 
candidates for earlier preventative interventions and more specific targeted therapies. While 
association studies can be useful in elucidating which genes play a role, eventually the 
combinations of many different genes will need to be examined in the context of disease. As 
technology advances, this type of research into subtle inter-individual genetic differences will 
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